What it's for (Indications)
- Prochlorperazine is clinically indicated for the management of severe nausea and vomiting from various etiologies, including postoperative nausea and vomiting, chemotherapy-induced nausea and vomiting (often as an adjunct to other antiemetics), and radiation therapy-induced emesis.
- It is also widely utilized for the symptomatic treatment of vertigo and dizziness associated with Ménière's disease and other labyrinthine disorders affecting the vestibular system.
- In specific psychiatric contexts and at appropriate dosages, it may be prescribed for the short-term treatment of non-psychotic anxiety and for the management of certain psychotic disorders, although its role in psychiatry has largely been superseded by newer agents with more favorable side effect profiles.
- The selection of prochlorperazine for these indications is based on its established efficacy in modulating key neurotransmitter pathways involved in emesis and balance.
- It is imperative that this medication is used strictly for approved indications and under the direct supervision of a healthcare professional to ensure patient safety and optimize therapeutic outcomes.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage regimens for prochlorperazine exhibit considerable variability depending on the specific indication, the chosen route of administration (oral, intramuscular, rectal), and individual patient factors such as age, renal and hepatic function, and the presence of co-morbidities. For the treatment of severe nausea and vomiting in adults, typical oral dosages range from 5 mg to 10 mg, administered three or four times daily, with a usual maximum total daily dose not exceeding 40 mg. In acute emetic episodes, intramuscular injections of 5 mg to 10 mg may be administered, potentially repeated after 6 hours, maintaining a maximum daily intramuscular dose generally around 40 mg. Rectal suppositories, commonly 25 mg, can be administered twice daily. For the management of vertigo, an oral dose of 5 mg three times daily is a common starting point. Pediatric dosages must be meticulously calculated based on body weight and age; prochlorperazine is generally not recommended for children under 2 years of age or weighing less than 9 kg due to increased risk of adverse effects. Long-term use, especially at higher doses, necessitates vigilant monitoring for potential adverse drug reactions. Patients must strictly adhere to prescribed dosages and consult their healthcare provider for any dosage adjustments or concerns. |
Safety & Warnings
Common Side Effects
- Prochlorperazine, a member of the phenothiazine class, is associated with a spectrum of potential side effects, which can vary in incidence and severity among individuals.
- Common adverse effects include central nervous system depression manifesting as drowsiness or sedation, dizziness, dry mouth, blurred vision, constipation, and orthostatic hypotension (a drop in blood pressure upon standing).
- A significant concern with prochlorperazine, particularly at higher doses or in susceptible individuals, is the development of extrapyramidal symptoms (EPS), which encompass acute dystonia (sustained muscle contractions), akathisia (motor restlessness), parkinsonism (tremor, rigidity, bradykinesia), and tardive dyskinesia, a potentially irreversible movement disorder characterized by involuntary, repetitive body movements.
- Other serious but rare adverse effects include neuroleptic malignant syndrome (NMS), a life-threatening condition presenting with fever, severe muscle rigidity, altered mental status, and autonomic instability.
- Endocrine disturbances such as hyperprolactinemia, galactorrhea, and amenorrhea may occur.
- Cardiovascular effects can include QT interval prolongation and cardiac arrhythmias.
- Hematologic effects, such as agranulocytosis, are rare but demand immediate medical attention.
- Patients should be educated to promptly report any unusual, severe, or persistent symptoms to their healthcare provider.
Serious Warnings
- Black Box Warning: WARNING: Increased Mortality in Elderly Patients with Dementia-Related Psychosis. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.
- Prochlorperazine carries several critical warnings and is contraindicated in specific patient populations.
- It is absolutely contraindicated in individuals with a known hypersensitivity to phenothiazines, in states of severe central nervous system depression or coma, and in patients presenting with blood dyscrasias.
- Extreme caution is warranted in elderly patients, particularly those with dementia-related psychosis, as prochlorperazine, like other antipsychotics, has been associated with an increased risk of mortality in this population, primarily due to cardiovascular events or infection.
- The risk of developing extrapyramidal symptoms (EPS), including potentially irreversible tardive dyskinesia, is a significant consideration, necessitating vigilant monitoring for these movement disorders throughout treatment.
- Neuroleptic Malignant Syndrome (NMS), though rare, is a potentially fatal complication requiring immediate discontinuation of the drug and intensive supportive care.
- Prochlorperazine can induce orthostatic hypotension, especially at the initiation of therapy or during dose escalation, thus requiring caution in patients with pre-existing cardiovascular conditions.
- It may also lower the seizure threshold and should be used with prudence in patients with a history of epilepsy or seizure disorders.
- Concomitant administration with other CNS depressants, including alcohol, can potentiate sedative effects.
- Patients must be advised against engaging in activities requiring mental alertness, such as driving or operating heavy machinery, until they ascertain how the medication affects their individual performance.
- Regular clinical monitoring is indispensable during treatment.
How it Works (Mechanism of Action)
Prochlorperazine, a prominent member of the piperazine phenothiazine derivative class, exerts its diverse therapeutic effects through complex and multi-receptor interactions within the central nervous system. Its potent antiemetic action, which is its primary clinical application at typical dosages, is predominantly mediated by the competitive antagonism of dopamine D2 receptors. This antagonism is particularly crucial within the chemoreceptor trigger zone (CTZ), located in the area postrema of the brainstem, a region responsible for initiating the vomiting reflex in response to circulating emetogenic substances and vestibular stimuli. By blocking these D2 receptors in the CTZ, prochlorperazine effectively inhibits the signaling cascade that would otherwise lead to nausea and vomiting. Beyond its robust D2 antagonism, prochlorperazine also exhibits significant blocking activity at histamine H1 receptors, which contributes to its sedative properties and provides additional antiemetic effects. Furthermore, it possesses anticholinergic properties through antagonism of muscarinic M1 cholinergic receptors, which can further ameliorate nausea and vomiting, but also contributes to side effects like dry mouth and constipation. The drug also exerts alpha-1 adrenergic receptor blocking activity, which can lead to adverse effects such as orthostatic hypotension. At higher doses or in susceptible individuals, its D2 receptor antagonism in other crucial brain regions, such as the mesolimbic and mesocortical pathways, contributes to its antipsychotic effects. This multifaceted receptor binding profile underpins prochlorperazine's efficacy in addressing a wide range of conditions from severe emesis to vertigo and, in specific contexts, certain psychiatric disorders.
Commercial Brands (Alternatives)
No other brands found for this formula.